Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation have?
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation has 43 citations in the OpenAlex counts ScholarIQ stores.
When was Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation published?
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation has 2015 year in the ScholarIQ index.
What is the open-access status of Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation?
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation has hybrid oa status in the ScholarIQ index.
What is the DOI of Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation?
The DOI for Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation is on the source record.
What is the PMID of Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation?
The PMID for Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation is on the source record.
What is the OpenAlex record for Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation?
The OpenAlex for Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation is on the source record.